Literature DB >> 3450842

Propranolol pharmacodynamic modeling using unbound and total concentrations in healthy volunteers.

R L Lalonde1, R J Straka, J A Pieper, M B Bottorff, D M Mirvis.   

Abstract

In an attempt to evaluate the propranolol (P) concentration-effect relationship, percentage reduction in exercise heart rate was modeled as a function of unbound and total P concentrations using the linear, Emax, and sigmoid Emax models. Nine volunteers underwent repeated treadmill exercise tests over 48 hr during a control period, after receiving 160 mg of P orally and again after receiving 160 mg once daily for 7 days. Beta blockade was assessed as the percentage reduction in exercise heart rate compared to control. Total serum P concentrations were determined by HPLC and unbound fractions by equilibrium dialysis. Using nonlinear least-squares regression, the Emax model was best in describing the concentration-effect relationship in each subject. Mean parameters for combined single dose and steady state were Emax 33.6 +/- 4.5% and EC50 18.2 +/- 15.6 ng/ml for total P and Emax 33.5 +/- 4.3% and EC50 1.66 +/- 1.56 for unbound P. Model fits were not significantly better for unbound versus total P and EC50 values showed similar intersubject variability. The observed unbound EC50 values are consistent with reported receptor dissociation constants. Therefore the large intersubject variability in EC50 could not be accounted for by variability in P protein binding.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3450842     DOI: 10.1007/BF01068413

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  20 in total

1.  Plasma concentrations and the time-course of beta blockade due to propranolol.

Authors:  D G McDevitt; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-12       Impact factor: 6.875

2.  Altered drug binding due to the use of indwelling heparinized cannulas (heparin lock) for sampling.

Authors:  M Wood; D G Shand; A J Wood
Journal:  Clin Pharmacol Ther       Date:  1979-01       Impact factor: 6.875

3.  Nonlinear pharmacokinetics of unbound propranolol after oral administration.

Authors:  R J Straka; R L Lalonde; J A Pieper; M B Bottorff; D M Mirvis
Journal:  J Pharm Sci       Date:  1987-07       Impact factor: 3.534

4.  Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man.

Authors:  J G Wagner
Journal:  J Theor Biol       Date:  1968-08       Impact factor: 2.691

5.  Errors in estimating the unbound fraction of drugs due to the volume shift in equilibrium dialysis.

Authors:  J D Huang
Journal:  J Pharm Sci       Date:  1983-11       Impact factor: 3.534

6.  Pharmacokinetic and pharmacodynamic studies with long-acting propranolol.

Authors:  J McAinsh; N S Baber; R Smith; J Young
Journal:  Br J Clin Pharmacol       Date:  1978-08       Impact factor: 4.335

7.  Effect of altered disopyramide binding on its pharmacologic response in rabbits.

Authors:  J D Huang; S Oie
Journal:  J Pharmacol Exp Ther       Date:  1982-11       Impact factor: 4.030

8.  Isoproterenol antagonism of cardioselective beta adrenergic receptor blocking agents: a comparative study of human and guinea-pig cardiac and bronchial beta adrenergic receptors.

Authors:  H H Harms
Journal:  J Pharmacol Exp Ther       Date:  1976-11       Impact factor: 4.030

9.  Propranolol dosage, plasma concentration, and beta blockade.

Authors:  J F Mullane; J Kaufman; D Dvornik; J Coelho
Journal:  Clin Pharmacol Ther       Date:  1982-12       Impact factor: 6.875

10.  Coexistence of beta 1- and beta 2-adrenoceptors in human right atrium. Direct identification by (+/-)-[125I]iodocyanopindolol binding.

Authors:  O E Brodde; K Karad; H R Zerkowski; N Rohm; J C Reidemeister
Journal:  Circ Res       Date:  1983-12       Impact factor: 17.367

View more
  4 in total

Review 1.  Pharmacodynamic modelling. Application to new drug development.

Authors:  P D Kroboth; V D Schmith; R B Smith
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

Review 2.  Risk assessment of adverse pulmonary effects induced by adrenaline beta-receptor antagonists and rational drug dosage regimen based on receptor occupancy.

Authors:  Y Yamada; K Matsuyama; K Ito; Y Sawada; T Iga
Journal:  J Pharmacokinet Biopharm       Date:  1995-10

3.  Pharmacokinetics and pharmacodynamics of conventional and controlled-release formulations of metipranolol in man.

Authors:  R Lapka; T Sechser; V Rejholec; M Peterková; M Votavová
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  Pharmacokinetic and pharmacodynamic modelling of metoprolol in rabbits with liver failure.

Authors:  A Bortolotti; D Castelli; D Verotta; M Bonati
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Apr-Jun       Impact factor: 2.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.